<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta name="keywords" content="" />
<meta name="description" content="" />
<meta http-equiv="content-type" content="text/html; charset=utf-8" />
<title>Neural Picks - Free AI Powered Stock Market Advice</title>
<link href="//fonts.googleapis.com/css?family=Abel|Arvo" rel="stylesheet" type="text/css" />
<link href="style.css" rel="stylesheet" type="text/css" media="screen" />
</head>
<body>
<div id="wrapper">
<div id="header">
<div id="logo">
<h1><a href="#">neural picks</a></h1>
</div>
</div>
<div id="about">
<h2 class="title">Updated on: 05/31/2021, 14:33:19</h2>
<p><img src="images/pics01.jpg" alt="" width="225" height="225" class="alignleft" /><strong>Disclaimer:</strong> This is a project for fun and none of the stock recommendations here should be executed using real money. I am not a professional stock advisor. All trading decisions and associated risks are your own, and I do not take responsibility for any losses.<br /><br /><strong>About:</strong> Stocks are ranked using Deep Learning according to performance on different quantitative and qualitative metrics. Stocks higher up on the list are predicted to have the highest returns over the next 3 weeks, but daily price swings can vary significantly. Forming a portfolio of multiple stocks can reduce daily risks.<br /><br /><strong>Contribute:</strong> Our mission is to further democratize finance by organizing high-quality publicly available information into actionable rankings. This information is free, however donations are highly appreciated at SegWit Bitcoin Wallet Address: bc1qxv7drjce5hx9l6eyht6ejtx2rex36an78fp82t</p>
<!-- AddToAny BEGIN -->
<div class="a2a_kit a2a_kit_size_32 a2a_default_style">
<a class="a2a_dd" href="https://www.addtoany.com/share"></a>
<a class="a2a_button_facebook"></a>
<a class="a2a_button_twitter"></a>
<a class="a2a_button_email"></a>
<a class="a2a_button_reddit"></a>
</div>
<script async src="https://static.addtoany.com/menu/page.js"></script>
<!-- AddToAny END --></div>
<div id="page">
<div id="content"><div class="post"><h2 class="title"><a href="#">MRNA</a></h2><p class="meta">Rank #1 | $185.01 / share</p><div class="entry">       <p>Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.</p>       <ul>
       <li>Robinhood Adjusted Rating: 47.761%</li>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Finnhub Adjusted Rating: 69.277%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 80.0%</li>
       <li>Social Media Sentiment: -63.51%</li>
       <li>Fair Stock Price Estimate: $191.62 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -52.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">TTD</a></h2><p class="meta">Rank #2 | $588.14 / share</p><div class="entry">       <p>The Trade Desk, Inc. operates as a technology company in the United States and internationally. The company operates a self-service cloud-based platform that allows buyers to create, manage, and optimize data-driven digital advertising campaigns in various advertising formats, including display, video, audio, native and social, and on various devices, such as computers, mobile devices, and connected TV. It also provides data and other value-added services, as well as platform features. The company serves advertising agencies and other service providers for advertisers. The Trade Desk, Inc. was founded in 2009 and is headquartered in Ventura, California.</p>       <ul>
       <li>Suggested By Multiple Sources</li>
       <li>Robinhood Adjusted Rating: 59.701%</li>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Finnhub Adjusted Rating: 64.375%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 79.46%</li>
       <li>Social Media Sentiment: 88.532%</li>
       <li>Recent Death Cross</li>
       <li>Fair Stock Price Estimate: $597.07 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -8.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">ATH</a></h2><p class="meta">Rank #3 | $62.63 / share</p><div class="entry">       <p>Athene Holding Ltd., a retirement services company, issues, reinsures, and acquires retirement savings products for individuals and institutions in the United States and Bermuda. The company provides annuity retirement solutions to its policyholders; and reinsures multi-year guaranteed annuities, fixed indexed annuities, traditional one-year guarantee fixed deferred annuities, immediate annuities, and institutional products. It also offers funding agreements and group annuities. The company was incorporated in 2008 and is headquartered in Pembroke, Bermuda.</p>       <ul>
       <li>Robinhood Adjusted Rating: 45.455%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 57.944%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Fair Stock Price Estimate: $101.96 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: 0.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">AMZN</a></h2><p class="meta">Rank #4 | $3223.07 / share</p><div class="entry">       <p>Amazon.com, Inc. engages in the retail sale of consumer products and subscriptions in North America and internationally. The company operates through three segments: North America, International, and Amazon Web Services (AWS). It sells merchandise and content purchased for resale from third-party sellers through physical and online stores. The company also manufactures and sells electronic devices, including Kindle, Fire tablets, Fire TVs, Rings, and Echo and other devices; provides Kindle Direct Publishing, an online service that allows independent authors and publishers to make their books available in the Kindle Store; and develops and produces media content. In addition, it offers programs that enable sellers to sell their products on its Websites, as well as its stores; and programs that allow authors, musicians, filmmakers, skill and app developers, and others to publish and sell content. Further, the company provides compute, storage, database, and other AWS services, as well as fulfillment, advertising, publishing, and digital content subscriptions. Additionally, it offers Amazon Prime, a membership program, which provides free shipping of various items; access to streaming of movies and TV episodes; and other services. The company also operates in the food delivery business in Bengaluru, India. It serves consumers, sellers, developers, enterprises, and content creators. The company also has utility-scale solar projects in China, Australia, and the United States. Amazon.com, Inc. was founded in 1994 and is headquartered in Seattle, Washington.</p>       <ul>
       <li>Robinhood Adjusted Rating: 96.97%</li>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Finnhub Adjusted Rating: 96.907%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 79.54%</li>
       <li>Social Media Sentiment: -53.701%</li>
       <li>Fair Stock Price Estimate: $3305.66 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -68.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">FB</a></h2><p class="meta">Rank #5 | $328.73 / share</p><div class="entry">       <p>Facebook, Inc. develops products that enable people to connect and share with friends and family through mobile devices, personal computers, virtual reality headsets, and in-home devices worldwide. The company's products include Facebook that enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers; Instagram, a community for sharing photos, videos, and private messages; Messenger, a messaging application for people to connect with friends, family, groups, and businesses across platforms and devices; and WhatsApp, a messaging application that is used by people and businesses to communicate in a private way. It also provides Oculus, a hardware, software, and developer ecosystem, which allows people to come together and connect with each other through its Oculus virtual reality products. Facebook, Inc. was founded in 2004 and is headquartered in Menlo Park, California.</p>       <ul>
       <li>Robinhood Adjusted Rating: 87.31%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 92.628%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 32.5%</li>
       <li>Social Media Sentiment: -90.512%</li>
       <li>Fair Stock Price Estimate: $334.83 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -76.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">RILY</a></h2><p class="meta">Rank #6 | $73.64 / share</p><div class="entry">       <p>B. Riley Financial, Inc., through its subsidiaries, provides collaborative financial services and solutions in North America, Australia, and Europe. The Capital Markets segments offers range of investment banking, corporate finance, consulting, financial advisory, research, securities lending, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. This segment also provides merger and acquisitions, restructuring advisory, initial and secondary public offerings, and institutional private placements services; asset management services; manages various private and public funds for institutional and individual investors; and trades in equity securities. The Auction and Liquidation Segment offers retail store liquidation, and wholesale and industrial assets disposition services. The Valuation and Appraisal segment provides valuation and appraisal services, which include valuation of assets to financial institutions, lenders, private equity firms, and other capital provider. The Principal Investments - United Online and magicJack segment provides consumer subscription services consisting of Internet access services and devices under the NetZero and Juno brands, as well as voice over IP cloud-based technology and communication services. The Brands segments provides licensing of a brand investment portfolio, including Catherine Malandrino, English Laundry, Joan Vass, Kensie Girl, Limited Too, and Nanette Lepore. In addition, it offers advisory services to private funds, and institutional and high net worth investors; brokerage services; senior secured and second lien secured loans to middle market public and the private U.S. companies; and consulting services to shareholders, creditors, and companies. The company was formerly known as Great American Group, Inc. and changed its name to B. Riley Financial, Inc. in November 2014. B. Riley Financial, Inc. was founded in 1973 and is headquartered in Los Angeles, California.</p>       <ul>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Fair Stock Price Estimate: $77.63 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: 28.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">ADBE</a></h2><p class="meta">Rank #7 | $504.58 / share</p><div class="entry">       <p>Adobe Inc. operates as a diversified software company worldwide. Its Digital Media segment provides tools and solutions that enable individuals, teams, and enterprises to create, publish, promote, and monetize their digital content. Its flagship product is Creative Cloud, a subscription service that allows customer to download and access the latest versions of its creative products. This segment serves content creators, experience designers, app developers, enthusiasts, students, social media users, and creative professionals, as well as marketing departments and agencies, companies and publishers. The company's Digital Experience segment offers products, services, and solutions for creating, managing, executing, measuring, monetizing and optimizing customer experiences from advertising to commerce. This segment serves marketers, advertisers, agencies, publishers, merchandisers, merchants, web analysts, data scientists, developers, marketing executives, information management and technology executives, product development executives, and sales and support executives. Its Publishing segment offers products and services, such as e-learning solutions, technical document publishing, web conferencing, document and forms platform, web application development, and high-end printing, as well as publishing needs of technical and business, and original equipment manufacturers (OEMs) printing businesses. The company offers its products and services directly to enterprise customers through its sales force and local field offices, as well as to end-users through app stores and through its Website at adobe.com. It also distributes products and services through a network of distributors, value-added resellers, systems integrators, software vendors and developers, retailers, and OEMs. The company was formerly known as Adobe Systems Incorporated and changed its name to Adobe Inc. in October 2018. The company was founded in 1982 and is headquartered in San Jose, California.</p>       <ul>
       <li>Robinhood Adjusted Rating: 84.848%</li>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Finnhub Adjusted Rating: 91.803%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 86.08%</li>
       <li>Social Media Sentiment: 50.048%</li>
       <li>Fair Stock Price Estimate: $512.59 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -44.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">MED</a></h2><p class="meta">Rank #8 | $332.25 / share</p><div class="entry">       <p>Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. It offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by Take Shape for Life, and Flavors of Home brands. The company markets its products through direct ecommerce platform and franchise weight control center channels. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.</p>       <ul>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 96.58%</li>
       <li>Social Media Sentiment: 37.991%</li>
       <li>Fair Stock Price Estimate: $345.29 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -16.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">GMAB</a></h2><p class="meta">Rank #9 | $40.62 / share</p><div class="entry">       <p>Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.</p>       <ul>
       <li>Robinhood Adjusted Rating: 69.388%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 83.396%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">ACN</a></h2><p class="meta">Rank #10 | $282.16 / share</p><div class="entry">       <p>Accenture plc, a professional services company, provides strategy and consulting, interactive, and technology and operations services worldwide. The company also provides outsourcing services. It serves communications, media, high tech, software, and platform companies; banking, capital market, and insurance industries; and consumer goods, retail, travel services, industrial, and life science industries, as well as clients in health, public service, chemicals and natural resources, energy, and utilities sectors. Accenture plc has alliance relationships with Adobe, Alibaba, Amazon Web Services, Blue Yonder, Cisco, Dell, Google, HPE, IBM RedHat, Microsoft, Oracle, Pegasystems, Salesforce, SAP, ServiceNow, VMWare, Workday, and Massachusetts Institute of Technology. The company was incorporated in 2009 and is based in Dublin, Ireland.</p>       <ul>
       <li>Robinhood Adjusted Rating: 66.019%</li>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Finnhub Adjusted Rating: 76.793%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 77.06%</li>
       <li>Social Media Sentiment: 46.208%</li>
       <li>Fair Stock Price Estimate: $295.15 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -4.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">ABNB</a></h2><p class="meta">Rank #11 | $140.4 / share</p><div class="entry">       <p>Airbnb, Inc. operates a platform for stays and experiences to guests worldwide. The company's marketplace model connects hosts and guests online or through mobile devices to book spaces and experiences. It primarily offers private rooms and luxury villas. The company was formerly known as AirBed & Breakfast, Inc. and changed its name to Airbnb, Inc. in November 2010. Airbnb, Inc. was founded in 2007 and is headquartered in San Francisco, California.</p>       <ul>
       <li>Robinhood Adjusted Rating: 40.0%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 57.447%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 88.88%</li>
       <li>Social Media Sentiment: 46.208%</li>
       <li>Insider Trading Transactions Rating: -36.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">IMAB</a></h2><p class="meta">Rank #12 | $81.07 / share</p><div class="entry">       <p>I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases. The company's product candidates in Phase I clinical trials include Enoblituzumab, a humanized B7-H3 antibody to treat immuno-oncology; TJ107, a long-acting recombinant human IL-7 to treat cancer treatment-related lymphopenia and cancer immunotherapy; TJC4, a CD47 monoclonal antibody with RBC-sparing differentiation; TJD5, a CD73 antibody for cancer treatment; and TJM2, a GM-CSF monoclonal antibody for rheumatoid arthritis and CAR-T-related therapies. Its product candidates in pre-clinical development comprise TJ210, an antibody targeting myeloid derived suppressor cells in cancers and autoimmune diseases; and TJX7, a novel CXCL13 antibody for autoimmune diseases. I-Mab has a collaboration agreement with AbbVie Inc. for the development and commercialization of TJC4, an anti-CD47 monoclonal antibody for the treatment of multiple cancers. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.</p>       <ul>
       <li>Robinhood Adjusted Rating: 100.0%</li>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Finnhub Adjusted Rating: 96.774%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       </ul>
</div></div></div>
</div>
</div>
<div id="footer">
<p>&copy; Jonathan Davies. All rights reserved. Design by <a href="http://templated.co" rel="nofollow">TEMPLATED</a>.</p>
</div>
</body>
</html>